The estimated Net Worth of Cynthia J Ladd is at least 768 千$ dollars as of 6 January 2020. Cynthia Ladd owns over 1,849 units of MyoKardia stock worth over 641,218$ and over the last 9 years Cynthia sold MYOK stock worth over 126,564$.
Cynthia has made over 3 trades of the MyoKardia stock since 2015, according to the Form 4 filled with the SEC. Most recently Cynthia sold 1,849 units of MYOK stock worth 126,564$ on 6 January 2020.
The largest trade Cynthia's ever made was exercising 4,700 units of MyoKardia stock on 1 January 2020 worth over 1,057,077$. On average, Cynthia trades about 1,194 units every 204 days since 2015. As of 6 January 2020 Cynthia still owns at least 2,851 units of MyoKardia stock.
You can see the complete history of Cynthia Ladd stock trades at the bottom of the page.
Cynthia's mailing address filed with the SEC is C/O MYOKARDIA, INC., 1000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 9 years, insiders at MyoKardia have traded over 313,807,381$ worth of MyoKardia stock and bought 2,317,816 units worth 42,556,877$ . The most active insiders traders include Sanofi、Kevin P Starr、Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of 21,462,936$. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth 469,900$.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
MyoKardia executives and other stock owners filed with the SEC include: